BG64338B1 - Производни на доластатин-15 в комбинация с таксани - Google Patents

Производни на доластатин-15 в комбинация с таксани Download PDF

Info

Publication number: BG64338B1
Authority: BG; Bulgaria
Prior art keywords: compound; formula; pro; tert; carbonyl
Prior art date: 1997-03-13

Application number

BG103728A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG103728A (en

Inventor

Teresa Barlozzari

Andreas Haupt

Original Assignee

Basf Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-13

Filing date

1999-09-13

Publication date

2004-10-29

1999-09-13 Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft

2000-04-28 Publication of BG103728A publication Critical patent/BG103728A/xx

2004-10-29 Publication of BG64338B1 publication Critical patent/BG64338B1/bg

Links

LQKSHSFQQRCAFW-CCVNJFHASA-N [(2s)-1-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxyl Chemical class C([C@@H]1N(C(=O)C=C1OC)C(=O)[C@@H](OC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)C1=CC=CC=C1 LQKSHSFQQRCAFW-CCVNJFHASA-N 0.000 title description 7
229940123237 Taxane Drugs 0.000 title description 6
150000001875 compounds Chemical class 0.000 claims abstract description 155
229930012538 Paclitaxel Natural products 0.000 claims abstract description 62
229960001592 paclitaxel Drugs 0.000 claims abstract description 62
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 62
206010028980 Neoplasm Diseases 0.000 claims abstract description 44
238000000034 method Methods 0.000 claims abstract description 35
238000011282 treatment Methods 0.000 claims abstract description 35
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims abstract description 21
239000000203 mixture Substances 0.000 claims abstract description 20
201000011510 cancer Diseases 0.000 claims abstract description 15
-1 2,2-dimethylglycyl Chemical group 0.000 claims description 205
239000008194 pharmaceutical composition Substances 0.000 claims description 27
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 27
239000003814 drug Substances 0.000 claims description 24
239000001257 hydrogen Substances 0.000 claims description 24
229910052739 hydrogen Inorganic materials 0.000 claims description 24
125000000217 alkyl group Chemical group 0.000 claims description 22
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
125000003545 alkoxy group Chemical group 0.000 claims description 21
229950003188 isovaleryl diethylamide Drugs 0.000 claims description 20
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 19
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 19
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 18
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
229940063683 taxotere Drugs 0.000 claims description 18
125000000753 cycloalkyl group Chemical group 0.000 claims description 17
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 16
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 16
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
229940079593 drug Drugs 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 11
150000002431 hydrogen Chemical class 0.000 claims description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
125000001424 substituent group Chemical group 0.000 claims description 10
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 9
229910052736 halogen Inorganic materials 0.000 claims description 9
150000002367 halogens Chemical class 0.000 claims description 9
238000002648 combination therapy Methods 0.000 claims description 8
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 8
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 8
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 7
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
210000002307 prostate Anatomy 0.000 claims description 7
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
210000001072 colon Anatomy 0.000 claims description 6
210000000664 rectum Anatomy 0.000 claims description 6
150000007513 acids Chemical class 0.000 claims description 5
210000000481 breast Anatomy 0.000 claims description 5
210000004072 lung Anatomy 0.000 claims description 5
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
210000003932 urinary bladder Anatomy 0.000 claims description 5
208000026310 Breast neoplasm Diseases 0.000 claims description 4
206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 4
208000029742 colonic neoplasm Diseases 0.000 claims description 4
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
125000001153 fluoro group Chemical group F* 0.000 claims description 4
125000003709 fluoroalkyl group Chemical group 0.000 claims description 4
201000005787 hematologic cancer Diseases 0.000 claims description 4
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
125000001072 heteroaryl group Chemical group 0.000 claims description 4
125000000623 heterocyclic group Chemical group 0.000 claims description 4
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
208000020816 lung neoplasm Diseases 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 claims description 3
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
125000003386 piperidinyl group Chemical group 0.000 claims description 3
230000002195 synergetic effect Effects 0.000 claims description 3
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 2
206010025323 Lymphomas Diseases 0.000 claims description 2
125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 claims description 2
125000002947 alkylene group Chemical group 0.000 claims description 2
125000001203 alloisoleucine group Chemical group 0.000 claims description 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
125000002619 bicyclic group Chemical group 0.000 claims description 2
239000004305 biphenyl Substances 0.000 claims description 2
235000010290 biphenyl Nutrition 0.000 claims description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
208000032839 leukemia Diseases 0.000 claims description 2
125000005412 pyrazyl group Chemical group 0.000 claims description 2
125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
125000005493 quinolyl group Chemical group 0.000 claims description 2
125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 claims description 2
125000002114 valyl group Chemical group 0.000 claims 9
206010006187 Breast cancer Diseases 0.000 claims 3
230000002357 endometrial effect Effects 0.000 claims 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
239000004727 Noryl Substances 0.000 claims 1
229920001207 Noryl Polymers 0.000 claims 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
238000011260 co-administration Methods 0.000 claims 1
UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 7
230000001093 anti-cancer Effects 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 117
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 63
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
108090000765 processed proteins & peptides Proteins 0.000 description 42
229920005989 resin Polymers 0.000 description 31
239000011347 resin Substances 0.000 description 31
RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 28
108010077112 prolyl-proline Proteins 0.000 description 28
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
239000000047 product Substances 0.000 description 24
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
150000001413 amino acids Chemical class 0.000 description 21
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 21
239000011541 reaction mixture Substances 0.000 description 21
239000000243 solution Substances 0.000 description 21
239000012074 organic phase Substances 0.000 description 18
230000015572 biosynthetic process Effects 0.000 description 17
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
210000004027 cell Anatomy 0.000 description 15
238000003786 synthesis reaction Methods 0.000 description 15
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
229910052938 sodium sulfate Inorganic materials 0.000 description 14
235000011152 sodium sulphate Nutrition 0.000 description 14
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
239000002904 solvent Substances 0.000 description 11
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
238000001914 filtration Methods 0.000 description 10
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
238000003776 cleavage reaction Methods 0.000 description 9
239000012634 fragment Substances 0.000 description 9
229910052757 nitrogen Inorganic materials 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
229920006395 saturated elastomer Polymers 0.000 description 9
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
125000004429 atom Chemical group 0.000 description 8
238000001704 evaporation Methods 0.000 description 8
230000008020 evaporation Effects 0.000 description 8
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 8
229910052763 palladium Inorganic materials 0.000 description 8
238000010647 peptide synthesis reaction Methods 0.000 description 8
125000006239 protecting group Chemical group 0.000 description 8
230000007017 scission Effects 0.000 description 8
238000001727 in vivo Methods 0.000 description 7
238000005406 washing Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
239000008346 aqueous phase Substances 0.000 description 6
239000012043 crude product Substances 0.000 description 6
125000004356 hydroxy functional group Chemical group O* 0.000 description 6
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 6
238000000746 purification Methods 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 5
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 5
102400001240 Inter-alpha-trypsin inhibitor light chain Human genes 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000008098 formaldehyde solution Substances 0.000 description 5
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
230000035484 reaction time Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
230000000259 anti-tumor effect Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
238000005984 hydrogenation reaction Methods 0.000 description 4
150000002576 ketones Chemical class 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000002054 transplantation Methods 0.000 description 4
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
108010016626 Dipeptides Proteins 0.000 description 3
LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 description 3
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
230000005526 G1 to G0 transition Effects 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
230000000118 anti-neoplastic effect Effects 0.000 description 3
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000011284 combination treatment Methods 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
108010045552 dolastatin 15 Proteins 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000013415 human tumor xenograft model Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
238000005932 reductive alkylation reaction Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 2
CANZBRDGRHNSGZ-NSHDSACASA-N (2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-NSHDSACASA-N 0.000 description 2
NNEHOKZDWLJKHP-LBPRGKRZSA-N (2s)-3-methyl-2-[methyl(phenylmethoxycarbonyl)amino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)N(C)C(=O)OCC1=CC=CC=C1 NNEHOKZDWLJKHP-LBPRGKRZSA-N 0.000 description 2
125000004400 (C1-C12) alkyl group Chemical group 0.000 description 2
125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000195493 Cryptophyta Species 0.000 description 2
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
208000002250 Hematologic Neoplasms Diseases 0.000 description 2
208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
APGLTERDKORUHK-LURJTMIESA-N N,N-dimethyl-L-Valine Chemical compound CC(C)[C@H](N(C)C)C(O)=O APGLTERDKORUHK-LURJTMIESA-N 0.000 description 2
KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
238000010976 amide bond formation reaction Methods 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000008512 biological response Effects 0.000 description 2
230000022534 cell killing Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 2
210000004696 endometrium Anatomy 0.000 description 2
238000000605 extraction Methods 0.000 description 2
125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 2
238000011010 flushing procedure Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
238000005227 gel permeation chromatography Methods 0.000 description 2
229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000011068 loading method Methods 0.000 description 2
208000003747 lymphoid leukemia Diseases 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000012264 purified product Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
QHRMEJWWMGUKAM-LURJTMIESA-N (2s)-2-(ethylazaniumyl)-3-methylbutanoate Chemical compound CCN[C@@H](C(C)C)C(O)=O QHRMEJWWMGUKAM-LURJTMIESA-N 0.000 description 1
FRYIZRQYLKRXTI-ZETCQYMHSA-N (2s)-2-[acetyl(methyl)amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)N(C)C(C)=O FRYIZRQYLKRXTI-ZETCQYMHSA-N 0.000 description 1
OQJJVXKMPUJFJK-BQBZGAKWSA-N (2s,3s)-2-(dimethylamino)-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N(C)C)C(O)=O OQJJVXKMPUJFJK-BQBZGAKWSA-N 0.000 description 1
UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical class C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
ITYQPPZZOYSACT-UHFFFAOYSA-N 2-(2,2-dimethylpropylamino)acetic acid Chemical compound CC(C)(C)CNCC(O)=O ITYQPPZZOYSACT-UHFFFAOYSA-N 0.000 description 1
XUWHRJBRJWTAPR-UHFFFAOYSA-N 2-(diethylazaniumyl)-3-methylbutanoate Chemical compound CCN(CC)C(C(C)C)C(O)=O XUWHRJBRJWTAPR-UHFFFAOYSA-N 0.000 description 1
IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
KWWFNGCKGYUCLC-UHFFFAOYSA-N 3,3-dimethyl-2-(methylamino)butanoic acid Chemical compound CNC(C(O)=O)C(C)(C)C KWWFNGCKGYUCLC-UHFFFAOYSA-N 0.000 description 1
KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
XNNPAWRINYCIHL-UHFFFAOYSA-N 3-carbamoyl-PROXYL Chemical compound CC1(C)CC(C(N)=O)C(C)(C)N1[O] XNNPAWRINYCIHL-UHFFFAOYSA-N 0.000 description 1
UIVWXNPUCAHAJX-UHFFFAOYSA-N 4-hydroxy-1,1-dioxo-2,5-diphenylthiophen-3-one Chemical compound O=S1(=O)C(C=2C=CC=CC=2)C(=O)C(O)=C1C1=CC=CC=C1 UIVWXNPUCAHAJX-UHFFFAOYSA-N 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
XKPVWBSHARELAV-UHFFFAOYSA-N C1CCCCC1N=C=NC1CCCCC1.C1CCCCC1N=C=NC1CCCCC1 Chemical compound C1CCCCC1N=C=NC1CCCCC1.C1CCCCC1N=C=NC1CCCCC1 XKPVWBSHARELAV-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
241000237378 Dolabella auricularia Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
206010066476 Haematological malignancy Diseases 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
229920001367 Merrifield resin Polymers 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
NAIPAPCKKRCMBL-JYJNAYRXSA-N Pro-Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CC=CC=C1 NAIPAPCKKRCMBL-JYJNAYRXSA-N 0.000 description 1
UOJYYXATTMQQNA-UHFFFAOYSA-N Proxan Chemical compound CC(C)OC(S)=S UOJYYXATTMQQNA-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
239000012317 TBTU Substances 0.000 description 1
241001116500 Taxus Species 0.000 description 1
241000202349 Taxus brevifolia Species 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000001118 alkylidene group Chemical group 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
229920003180 amino resin Polymers 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000011717 athymic nude mouse Methods 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
DMSMPAJRVJJAGA-UHFFFAOYSA-N benzo[d]isothiazol-3-one Chemical compound C1=CC=C2C(=O)NSC2=C1 DMSMPAJRVJJAGA-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229960000935 dehydrated alcohol Drugs 0.000 description 1
XUWHAWMETYGRKB-UHFFFAOYSA-N delta-valerolactam Chemical group O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
SYZWSSNHPZXGML-UHFFFAOYSA-N dichloromethane;oxolane Chemical compound ClCCl.C1CCOC1 SYZWSSNHPZXGML-UHFFFAOYSA-N 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229930004069 diterpene Natural products 0.000 description 1
150000004141 diterpene derivatives Chemical class 0.000 description 1
AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
229930188854 dolastatin Natural products 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000037219 healthy weight Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000010501 iterative synthesis reaction Methods 0.000 description 1
TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
150000003951 lactams Chemical class 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
BLWYXBNNBYXPPL-YFKPBYRVSA-N methyl (2s)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1 BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 description 1
HQEIPVHJHZTMDP-JEDNCBNOSA-N methyl (2s)-pyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@@H]1CCCN1 HQEIPVHJHZTMDP-JEDNCBNOSA-N 0.000 description 1
230000029115 microtubule polymerization Effects 0.000 description 1
XJODGRWDFZVTKW-ZCFIWIBFSA-N n-methylleucine Chemical compound CN[C@@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-ZCFIWIBFSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
230000036185 rubor Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000007761 synergistic anti-cancer Effects 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
230000029305 taxis Effects 0.000 description 1
NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 1
150000003953 γ-lactams Chemical group 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Epoxy Compounds (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG103728A 1997-03-13 1999-09-13 Производни на доластатин-15 в комбинация с таксани BG64338B1 (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/819,101 US6103698A (en)	1997-03-13	1997-03-13	Dolastatin-15 derivatives in combination with taxanes

Publications (2)

Publication Number	Publication Date
BG103728A BG103728A (en)	2000-04-28
BG64338B1 true BG64338B1 (bg)	2004-10-29

Family

ID=25227196

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103728A BG64338B1 (bg)	1997-03-13	1999-09-13	Производни на доластатин-15 в комбинация с таксани

Country Status (29)

Country	Link
US (2)	US6103698A (de)
EP (1)	EP0981358B1 (de)
JP (1)	JP2001514659A (de)
KR (1)	KR100555604B1 (de)
CN (1)	CN1157223C (de)
AT (1)	ATE241376T1 (de)
AU (1)	AU728027B2 (de)
BG (1)	BG64338B1 (de)
BR (1)	BR9808249A (de)
CA (1)	CA2282720C (de)
CO (1)	CO4940498A1 (de)
CZ (1)	CZ293905B6 (de)
DE (1)	DE69815100T2 (de)
DK (1)	DK0981358T3 (de)
ES (1)	ES2200317T3 (de)
HR (1)	HRP980125A2 (de)
HU (1)	HU228860B1 (de)
ID (1)	ID23900A (de)
IL (2)	IL131597A0 (de)
NO (1)	NO323894B1 (de)
NZ (1)	NZ337416A (de)
PL (1)	PL197834B1 (de)
PT (1)	PT981358E (de)
RU (1)	RU2218174C2 (de)
SK (1)	SK285133B6 (de)
TR (1)	TR199902244T2 (de)
TW (1)	TWI277426B (de)
WO (1)	WO1998040092A1 (de)
ZA (1)	ZA982093B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010009901A1 (en)	1996-12-11	2001-07-26	Basf Aktiengesellschaft Germany	Antineoplastic peptides
EP2266607A3 (de)	1999-10-01	2011-04-20	Immunogen, Inc.	Immunokonjugate für Krebsbehandlung
US20050192443A1 (en) *	2000-11-08	2005-09-01	Lorus Therapeutics Inc.	Biological response modifier for the treatment of cancer
WO2002038164A1 (en) *	2000-11-08	2002-05-16	Lorus Therapeutics Inc.	Combination preparation of a biological response modifier and an anticancer agent and uses thereof
US7772177B2 (en)	2005-05-18	2010-08-10	Aegera Therapeutics, Inc.	BIR domain binding compounds
SG171682A1 (en)	2006-05-16	2011-06-29	Aegera Therapeutics Inc	Iap bir domain binding compounds
JP5841072B2 (ja)	2010-02-10	2016-01-06	イミュノジェン・インコーポレーテッド	Ｃｄ２０抗体およびその使用
EP3263583A1 (de)	2010-02-12	2018-01-03	Pharmascience Inc.	Iap-bir-domänen bindende verbindungen
TW202210498A (zh) *	2020-06-03	2022-03-16	日商中外製藥股份有限公司	高難度序列之有效率的胜肽縮合法
MX2024002571A (es)	2021-09-03	2024-03-20	Toray Industries	Composicion farmaceutica para tratamiento y/o prevencion de cancer.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816444A (en) *	1987-07-10	1989-03-28	Arizona Board Of Regents, Arizona State University	Cell growth inhibitory substance
US5676978A (en)	1989-02-14	1997-10-14	Amira, Inc.	Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US4879278A (en) *	1989-05-16	1989-11-07	Arizona Board Of Regents	Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5278324A (en) *	1990-08-28	1994-01-11	Virginia Tech Intellectual Properties, Inc.	Water soluble derivatives of taxol
MX9102128A (es)	1990-11-23	1992-07-08	Rhone Poulenc Rorer Sa	Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
SG87056A1 (en)	1991-08-09	2002-03-19	Teikoku Hormone Mfg Co Ltd	Novel tetrapeptide derivative
US5227400A (en) *	1991-09-23	1993-07-13	Florida State University	Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5250683A (en) *	1991-09-23	1993-10-05	Florida State University	Certain substituted taxanes and pharmaceutical compositions containing them
US5272171A (en) *	1992-02-13	1993-12-21	Bristol-Myers Squibb Company	Phosphonooxy and carbonate derivatives of taxol
FR2688518B1 (fr) *	1992-03-13	1994-05-06	Rhone Poulenc Rorer Sa	Procede de preparation de derives du taxane.
US5831002A (en) *	1992-05-20	1998-11-03	Basf Aktiengesellschaft	Antitumor peptides
US5248796A (en) *	1992-06-18	1993-09-28	Bristol-Myers Squibb Company	Taxol derivatives
US5254580A (en) *	1993-01-19	1993-10-19	Bristol-Myers Squibb Company	7,8-cyclopropataxanes
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
AU679479B2 (en) *	1992-12-16	1997-07-03	Basf Aktiengesellschaft	Dolostatin analog
US5484612A (en) *	1993-09-22	1996-01-16	The Board Of Trustees Of The Leland Stanford Junior University	Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
CA2129282A1 (en)	1993-09-29	1995-03-30	George Weber	Method for the treatment of neoplastic disease utilizing taxol and tiazofurin
US5447936A (en) *	1993-12-22	1995-09-05	Bionumerik Pharmaceuticals, Inc.	Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5565478A (en) *	1994-03-14	1996-10-15	The United States Of America As Represented By The Department Of Health & Human Services	Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5494930A (en) *	1994-06-02	1996-02-27	Shimizu; Yuzuru	Caribenolide I
US5525613A (en) *	1994-06-16	1996-06-11	Entropin, Inc.	Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5530097A (en) *	1994-08-01	1996-06-25	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory peptide amides
US5504191A (en) *	1994-08-01	1996-04-02	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide methyl esters
US5543423A (en) *	1994-11-16	1996-08-06	Vertex Pharmaceuticals, Incorporated	Amino acid derivatives with improved multi-drug resistance activity
ATE306927T1 (de)	1994-12-15	2005-11-15	Baker Norton Pharma	Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung

1997
- 1997-03-13 US US08/819,101 patent/US6103698A/en not_active Expired - Lifetime
1998
- 1998-03-09 IL IL13159798A patent/IL131597A0/xx active IP Right Grant
- 1998-03-09 PL PL335579A patent/PL197834B1/pl unknown
- 1998-03-09 ES ES98909066T patent/ES2200317T3/es not_active Expired - Lifetime
- 1998-03-09 JP JP53967998A patent/JP2001514659A/ja active Pending
- 1998-03-09 DE DE69815100T patent/DE69815100T2/de not_active Expired - Lifetime
- 1998-03-09 RU RU99122032/14A patent/RU2218174C2/ru not_active IP Right Cessation
- 1998-03-09 BR BR9808249-3A patent/BR9808249A/pt not_active IP Right Cessation
- 1998-03-09 CA CA002282720A patent/CA2282720C/en not_active Expired - Fee Related
- 1998-03-09 CZ CZ19993211A patent/CZ293905B6/cs not_active IP Right Cessation
- 1998-03-09 ID IDW991020A patent/ID23900A/id unknown
- 1998-03-09 NZ NZ337416A patent/NZ337416A/en not_active IP Right Cessation
- 1998-03-09 SK SK1251-99A patent/SK285133B6/sk not_active IP Right Cessation
- 1998-03-09 TR TR1999/02244T patent/TR199902244T2/xx unknown
- 1998-03-09 AT AT98909066T patent/ATE241376T1/de active
- 1998-03-09 PT PT98909066T patent/PT981358E/pt unknown
- 1998-03-09 AU AU66945/98A patent/AU728027B2/en not_active Ceased
- 1998-03-09 KR KR1019997008305A patent/KR100555604B1/ko not_active Expired - Fee Related
- 1998-03-09 CN CNB988033089A patent/CN1157223C/zh not_active Expired - Fee Related
- 1998-03-09 HU HU0001381A patent/HU228860B1/hu not_active IP Right Cessation
- 1998-03-09 DK DK98909066T patent/DK0981358T3/da active
- 1998-03-09 EP EP98909066A patent/EP0981358B1/de not_active Expired - Lifetime
- 1998-03-09 WO PCT/US1998/004594 patent/WO1998040092A1/en not_active Ceased
- 1998-03-10 HR HR08/819,101A patent/HRP980125A2/hr not_active Application Discontinuation
- 1998-03-12 ZA ZA9802093A patent/ZA982093B/xx unknown
- 1998-03-12 CO CO98013903A patent/CO4940498A1/es unknown
- 1998-03-13 TW TW087103777A patent/TWI277426B/zh not_active IP Right Cessation
1999
- 1999-08-26 IL IL131597A patent/IL131597A/en not_active IP Right Cessation
- 1999-09-10 NO NO19994408A patent/NO323894B1/no not_active IP Right Cessation
- 1999-09-13 BG BG103728A patent/BG64338B1/bg unknown
2000
- 2000-03-07 US US09/520,254 patent/US6632795B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2200317T3 (es)	2004-03-01
DE69815100T2 (de)	2004-02-05
SK125199A3 (en)	2000-08-14
CO4940498A1 (es)	2000-07-24
CA2282720C (en)	2009-12-29
KR20000076211A (ko)	2000-12-26
CZ293905B6 (cs)	2004-08-18
BR9808249A (pt)	2000-05-16
CA2282720A1 (en)	1998-09-17
HUP0001381A2 (hu)	2000-10-28
CZ321199A3 (cs)	2000-02-16
BG103728A (en)	2000-04-28
ID23900A (id)	2000-05-25
PT981358E (pt)	2003-09-30
EP0981358A1 (de)	2000-03-01
SK285133B6 (sk)	2006-07-07
HK1026851A1 (en)	2000-12-29
HUP0001381A3 (en)	2001-12-28
RU2218174C2 (ru)	2003-12-10
US6103698A (en)	2000-08-15
NZ337416A (en)	2001-05-25
KR100555604B1 (ko)	2006-03-03
CN1252728A (zh)	2000-05-10
ATE241376T1 (de)	2003-06-15
TR199902244T2 (xx)	1999-12-21
IL131597A (en)	2006-06-11
JP2001514659A (ja)	2001-09-11
HU228860B1 (en)	2013-06-28
IL131597A0 (en)	2001-01-28
WO1998040092A1 (en)	1998-09-17
HRP980125A2 (en)	1999-02-28
DE69815100D1 (de)	2003-07-03
EP0981358B1 (de)	2003-05-28
NO323894B1 (no)	2007-07-16
PL197834B1 (pl)	2008-04-30
NO994408L (no)	1999-11-10
AU728027B2 (en)	2001-01-04
AU6694598A (en)	1998-09-29
ZA982093B (en)	1999-09-12
US6632795B1 (en)	2003-10-14
TWI277426B (en)	2007-04-01
CN1157223C (zh)	2004-07-14
PL335579A1 (en)	2000-05-08
NO994408D0 (no)	1999-09-10
DK0981358T3 (da)	2003-09-22

Publication	Publication Date	Title
IL107987A (en)	1999-10-28	Dolastatin analogs their preparation and pharmaceutical compositions containing them
AU669710B2 (en)	1996-06-20	Derivatives of dolastatin
EP0981358B1 (de)	2003-05-28	Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten
AU748465B2 (en)	2002-06-06	Methods and compositions for treating rheumatoid arthritis
EP0866800B1 (de)	2004-09-22	Antineoplastische peptide
US8440626B2 (en)	2013-05-14	Antineoplastic peptides
MXPA99008066A (en)	2000-06-01	Dolastatin-15 derivatives in combination with taxanes
HK1080871A (en)	2006-05-04	Antineoplastic peptides
CZ20001211A3 (cs)	2001-06-13	Prostředky pro léčení revmatoidní artritidy
PL178351B1 (pl)	2000-04-28	Nowe peptydy